Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer
Open Access
- 1 November 2018
- journal article
- research article
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. ume 9, 103-110
Abstract
Purpose: To report the outcomes of stereotactic body radiation therapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) according to respiratory motion management method. Methods: Patients with stage I NSCLC who received SBRT from 2007 to 2015 were reviewed. Computed tomography (CT) simulation with four-dimensional CT was performed for respiratory motion assessment. Tumor motion >1 cm in the craniocaudal direction was selectively treated with advanced respiratory management: either respiratory gating to a pre-specified portion of the respiratory cycle or dynamic tracking of an implanted fiducial marker. Comparisons were made with internal target volume approach, which treated all phases of respiratory motion. Results: Of 297 patients treated with SBRT at our institution, 51 underwent advanced respiratory management (48 with respiratory gating and three with tumor tracking) and 246 underwent all-phase treatment. Groups were similarly balanced with regard to mean age (P=0.242), tumor size (P=0.315), and histology (P=0.715). Tumor location in the lower lung lobes, as compared to middle or upper lobes, was more common in those treated with advanced respiratory management (78.4%) compared to all-phase treatment (25.6%, PP=0.56), mean time to any failure (73.2 vs 78.7 months, P=0.73), or median overall survival (43.3 vs 45.5 months, P=0.56) between patients who underwent advanced respiratory motion management and all-phase treatment. Conclusion: SBRT with advanced respiratory management (the majority with respiratory gating) showed similar efficacy to all-phase treatment approach for stage I NSCLC.Keywords
This publication has 32 references indexed in Scilit:
- Stereotactic Body Radiation Therapy for Stage I Non–Small Cell Lung CancerThoracic Surgery Clinics, 2016
- A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsThe Lancet Oncology, 2015
- Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic ExperienceJournal of Thoracic Oncology, 2009
- Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body RadiotherapyJournal of Clinical Oncology, 2009
- Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional StudyJournal of Thoracic Oncology, 2007
- Extracranial Stereotactic Radioablation *Chest, 2003